Novo Nordisk Sues Lilly Over GLP-1 Ads | Mesa News

Mesa News Today | 2 Min News | The Daily News Now! · Jul 23, 2026 · 1m

Novo Nordisk is suing Eli Lilly over aggressive advertising claims for Mounjaro and Zepbound, accusing them of spreading false info by comparing their drugs to Ozempic and Wegovy using outdated, low-dose studies. Lilly fires back, insisting their ads are science-backed and truthful, citing their own head-to-head trial showing Zepbound’s superior weight loss. The legal showdown, now in a New Jersey federal court, pits two titans of the GLP-1 weight-loss drug race — with Novo arguing Lilly’s claims are misleading and outdated, while Lilly stands firm on transparency and patient benefit. Listen…